Envoy Medical (NASDAQ:COCH) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Envoy Medical (NASDAQ:COCH – Free Report) to a sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Envoy Medical in a report on Thursday, October 30th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $9.50.

Check Out Our Latest Research Report on COCH

Envoy Medical Trading Down 0.3%

Shares of NASDAQ COCH opened at $0.70 on Friday. The company has a market cap of $17.97 million, a P/E ratio of -0.49 and a beta of 2.09. Envoy Medical has a 12-month low of $0.69 and a 12-month high of $2.32. The stock has a fifty day moving average price of $0.97 and a 200 day moving average price of $1.30.

Envoy Medical (NASDAQ:COCH – Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.04). On average, sell-side analysts forecast that Envoy Medical will post -1.21 EPS for the current fiscal year.

Institutional Trading of Envoy Medical

An institutional investor recently bought a new position in Envoy Medical stock. NorthRock Partners LLC bought a new stake in shares of Envoy Medical, Inc. (NASDAQ:COCH – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 10,290,049 shares of the company’s stock, valued at approximately $14,612,000. NorthRock Partners LLC owned 48.25% of Envoy Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 8.59% of the company’s stock.

About Envoy Medical

(Get Free Report)

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.

Further Reading